Eli Lilly's existing 2024 research collaboration with Peptron grants only a non-exclusive license for internal evaluation of SmartDepot's sustained-release microsphere technology on peptide drugs, with no confirmed path to a commercial deal. Traders see the 87.5% probability of no full licensing by the early-October 2026 deadline as driven by Lilly's strategic pivot toward oral obesity candidates, ongoing uncertainty around technology evaluation timelines, and the absence of recent regulatory filings, partnership announcements, or supply-chain signals. The short window leaves little room for the multi-month negotiations, IP reviews, and milestone validations typical in pharma licensing, reinforcing market consensus around the status quo.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日$11,264 Vol.
$11,264 Vol.
$11,264 Vol.
$11,264 Vol.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
マーケット開始日: May 5, 2026, 8:02 PM ET
Resolver
0x65070BE91...Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...Eli Lilly's existing 2024 research collaboration with Peptron grants only a non-exclusive license for internal evaluation of SmartDepot's sustained-release microsphere technology on peptide drugs, with no confirmed path to a commercial deal. Traders see the 87.5% probability of no full licensing by the early-October 2026 deadline as driven by Lilly's strategic pivot toward oral obesity candidates, ongoing uncertainty around technology evaluation timelines, and the absence of recent regulatory filings, partnership announcements, or supply-chain signals. The short window leaves little room for the multi-month negotiations, IP reviews, and milestone validations typical in pharma licensing, reinforcing market consensus around the status quo.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日


外部リンクに注意してください。
外部リンクに注意してください。
よくある質問